Author + information
- Received July 13, 2012
- Revision received September 18, 2012
- Accepted September 27, 2012
- Published online January 15, 2013.
- Tal Hasin, MD⁎,
- Yariv Marmor, PhD†,
- Walter Kremers, PhD†,
- Yan Topilsky, MD⁎,
- Cathy J. Severson, RN, BSN‡,
- John A. Schirger, MD⁎,
- Barry A. Boilson, MD⁎,
- Alfredo L. Clavell, MD⁎,
- Richard J. Rodeheffer, MD⁎,
- Robert P. Frantz, MD⁎,
- Brooks S. Edwards, MD⁎,
- Naveen L. Pereira, MD⁎,
- John M. Stulak, MD‡,
- Lyle Joyce, MD‡,
- Richard Daly, MD‡,
- Soon J. Park, MD‡ and
- Sudhir S. Kushwaha, MD⁎,⁎ ()
- ↵⁎Reprint requests and correspondence:
Dr. Sudhir S. Kushwaha, Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905
Objectives The purpose of this study was to determine the occurrence and causes of readmissions after implantation of axial flow left ventricular assist device (LVAD).
Background Based on the REMATCH (Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure) study experience, readmissions after LVAD implantation are thought to be frequent.
Methods We retrospectively analyzed admissions to our facility in a cohort of 115 patients implanted between January 2008 and July 2011 with the HeartMate II axial flow LVAD, of whom 42 were bridged to transplant. To account for repeated events, Andersen-Gill models were used to determine possible predictors.
Results The patients were followed for 1.4 ± 0.9 years. There were 224 readmissions in 83 patients. The overall readmission rate was 1.64 ± 1.97 per patient-year of follow-up. The readmission rate for the first 6 months was 2.0 ± 2.3 and decreased to 1.2 ± 2.1 during subsequent follow-up. Leading causes were bleeding (66 readmissions in 34 patients), mostly gastrointestinal bleed (51 in 27 patients), cardiac (51 in 36 patients, most for HF or arrhythmia), infections (32 in 25 patients) of which 6 were pump related, and thrombosis (20 in 15 patients) including 13 readmissions due to hemolysis. Preoperative variables associated with (fewer) readmissions in a multivariate model include residence within our hospital-extended referral zone of Minnesota and the neighboring states (hazard ratio: 0.66; 95% confidence interval: 0.48 to 0.91; p = 0.011), hemoglobin (hazard ratio: 0.91, 95% confidence interval: 0.84 to 0.99; p = 0.027) and N-terminal pro–B-type natriuretic peptide (hazard ratio: 0.98; 95% confidence interval: 0.96 to 1.0 per 1,000-unit increase, p = 0.022). C-statistic for the model: 0.63.
Conclusions Readmission rates after axial flow LVAD implantation decrease during the first 6 months and then stabilize. The leading causes are bleeding, cardiac (heart failure and arrhythmia), infections, and thrombosis.
Drs. Hasin, Kushwaha, Park, and Joyce have received a research grant from Thoratec. Dr. Frantz is a consultant for Pfizer and has received research funding from United Therapeutics. Dr. Park is a consultant for Thoratec. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received July 13, 2012.
- Revision received September 18, 2012.
- Accepted September 27, 2012.
- American College of Cardiology Foundation